Facebook
Twitter
LinkedIn
Forward
Parkinson’s Disease Psychosis: A New Outlook on Early Screening and Treatment (CME/CE Monograph)
Activity Description and Purpose
This educational activity is focused on the practical aspects of identification and treatment of Parkinson’s disease psychosis (PDP). A combination of text and short video cases interspersed with questions will help clinicians learn how to use a new, validated, self-administered, 4-question screening tool for PDP in practice and make appropriate treatment decisions for those with PDP. At the end of this activity, clinicians will recognize how to treat symptoms of PDP earlier and more effectively while maintaining safety and quality of life.
Target Audience
This educational activity is intended for movement disorder specialists and other neurologists, primary care physicians, nurse practitioners, nurses, physician assistants, and other clinicians treating patients with Parkinson’s disease in outpatient and long-term care settings.
Learning Objectives
After completing this activity, participants will be better able to:
- Describe the components of a new screening tool for Parkinson’s disease psychosis
- Use the SASPAP in case-based scenarios to identify symptoms of psychosis in Parkinson’s disease
- Apply the latest evidence to individualize care of patients with Parkinson’s disease psychosis
- Modify treatment regimens of patients treated for Parkinson’s disease psychosis with an off-label antipsychotic
Faculty
 | Alberto Espay, MD (Co-Chair)
|
 | William Ondo, MD
|
Disclosure Policy
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Faculty
Alberto Espay, MD, is a consultant for ACADIA Pharmaceuticals Inc, Acorda Therapeutics, Amneal Pharmaceuticals LLC, Avion Pharmaceuticals, Herantis Pharma Plc, Kyowa Kirin International plc, NeuroDerm, Praxis Precision Medicines, Sunovion Pharmaceuticals Inc, and Supernus Pharmaceuticals, Inc; is an advisory board member of ACADIA Pharmaceuticals Inc, Acorda Therapeutics, Amneal Pharmaceuticals LLC, Avion Pharmaceuticals, Herantis Pharma Plc, Kyowa Kirin International plc, NeuroDerm, Praxis Precision Medicines, Sunovion Pharmaceuticals Inc, and Supernus Pharmaceuticals; and is a contracted researcher for the Michael J. Fox Foundation.
William Ondo, MD, is a consultant for AbbVie Inc, Amneal Pharmaceuticals LLC, Jazz Pharmaceuticals Inc, Merz, Inc, Revance Therapeutics, Inc, and Supernus Pharmaceuticals, Inc; and is on the speakers bureau for ACADIA Pharmaceuticals, Inc, Kyowa Kirin Co, Ltd, Neurocrine Biosciences, Inc, and Teva Pharmaceutical Industries Ltd.
Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners, Managers, and Writers
MedEdicus and Amedco planners, managers, and writers have no relevant commercial relationships to disclose.
Satisfactory Completion
Learners must take the pretest, read the monograph, and complete the posttest and evaluation form to receive a certificate of completion. You must complete the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
For Physicians
ACCME Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA PRA Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For Nurses
Interprofessional Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by MedEdicus LLC and Amedco LLC. Amedco LLC is jointly accredited by the ACCME, the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Amedco Joint Accreditation #4008163.
Nurses (ANCC) Credit Designation
Amedco LLC designates this activity for a maximum of 0.75 ANCC contact hour.
Nurse Practitioners
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from ACADIA Pharmaceuticals Inc.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing inforation for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC, Amedco LLC, or ACADIA Pharmaceuticals Inc.
©2024 MedEdicus LLC. 327
Available Credit
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC
- 0.75 Participation